How to Lower Triglycerides Specifically
Start with aggressive lifestyle modification as the foundation: reduce refined carbohydrates and added sugars to <5-10% of calories, increase omega-3 rich foods, achieve weight loss if overweight, eliminate alcohol, and engage in moderate-to-high intensity physical activity. 1, 2
Lifestyle Interventions (First-Line for All Patients)
The most direct approach to lowering triglycerides involves targeted dietary changes:
Dietary Modifications
- Carbohydrate restriction: Dramatically reduce refined carbohydrates and added sugars. For triglycerides 500-999 mg/dL, limit added sugars to <5% of calories; for ≥1,000 mg/dL, eliminate added sugars entirely 1
- Fat intake adjustment:
- For triglycerides 500-999 mg/dL: 20-25% of calories from fat
- For triglycerides ≥1,000 mg/dL: 10-15% of calories from fat (may need extreme restriction to <5% until levels drop below 1,000 mg/dL) 1
- Increase omega-3 fatty acids: Consume foods rich in omega-3s (fatty fish), though dietary supplements are not recommended for mild-moderate hypertriglyceridemia without ASCVD 1
- Alcohol elimination: Complete abstinence, as alcohol directly stimulates hepatic VLDL triglyceride secretion 3, 4
Physical Activity
Moderate-to-high intensity exercise lowers triglycerides while improving body composition 2
Weight Loss
If overweight or obese, weight reduction is critical 2
Pharmacotherapy Algorithm
For Mild-Moderate Hypertriglyceridemia (150-499 mg/dL)
Statins are the first-choice medication, even though they are not primary triglyceride-lowering drugs 1. The rationale: statins provide a relatively constant LDL-C/triglyceride-lowering ratio, so higher-intensity statins produce greater triglyceride reduction 1.
- Calculate 10-year ASCVD risk to guide statin initiation
- For borderline (5-7.4%) or intermediate (7.5-19.9%) risk: consider statins 2
- For high-risk patients with residual hypertriglyceridemia on maximally tolerated statin: Add high-dose icosapent ethyl (purified EPA), which reduces cardiovascular mortality (NNT=111 over 5 years) 2, 5
Important caveat: Omega-3 fatty acid dietary supplements have no proven benefit for ASCVD risk reduction or triglyceride lowering in patients aged 40-75 without ASCVD or diabetes 1. Only prescription icosapent ethyl has demonstrated cardiovascular benefit 5.
For Severe Hypertriglyceridemia (≥500 mg/dL)
The primary goal shifts to pancreatitis prevention rather than cardiovascular risk reduction 1, 3.
Pharmacotherapy options (though evidence for pancreatitis prevention is limited):
- Fibrates: First-line pharmacologic option 2
- Prescription omega-3 fatty acids: FDA-approved for triglycerides ≥500 mg/dL 6
- Niacin: Alternative option 2
These agents work by reducing triglyceride synthesis and VLDL secretion in the liver, but have limited effectiveness when triglycerides ≥1,000 mg/dL because they don't clear circulating chylomicrons 1.
For Very Severe Hypertriglyceridemia (≥1,000 mg/dL)
Extreme dietary fat restriction (<5% of total calories) takes priority until levels drop below 1,000 mg/dL 1. Pharmacotherapy effectiveness is markedly limited at these levels.
Critical Secondary Causes to Address
Before or concurrent with treatment, identify and manage:
- Diabetes/hyperglycemia: Optimize glycemic control first, as insulin insufficiency with markedly elevated triglycerides requires treating hyperglycemia before reassessing hypertriglyceridemia 1, 3
- Hypothyroidism 3
- Nephrotic syndrome or renal failure 3
- Medications: Discontinue or substitute thiazide diuretics, beta-blockers (especially atenolol, metoprolol, propranolol), oral estrogens, retinoids, bile acid sequestrants 3
- Obesity and metabolic syndrome 2
Common Pitfalls to Avoid
Don't use bile acid sequestrants in patients with severe hypertriglyceridemia (≥1,000 mg/dL) or dysbetalipoproteinemia—they worsen hypertriglyceridemia 3
Don't assume all omega-3 products are equivalent: Only icosapent ethyl has cardiovascular outcome data; mixed EPA/DHA formulations have not shown benefit 5, 7
Don't overlook that triglyceride lowering alone doesn't guarantee cardiovascular benefit unless accompanied by reduction in atherogenic apoB-containing lipoproteins 7
For women of childbearing age: Oral estrogens can provoke severe pancreatitis in those with familial hypertriglyceridemia or LpL deficiency 3
Monitoring Approach
After implementing lifestyle changes and/or pharmacotherapy, reassess triglyceride levels to determine if the target has been achieved and adjust therapy accordingly. For patients with triglycerides 500-999 mg/dL, individualized Medical Nutrition Therapy is essential, as response varies based on the balance of glycemic control, carbohydrate quality/quantity, and total fat content 1.